Articles tagged with Cancer Immunotherapy
Researchers have developed novel liquid metal nanoparticles that combine photothermal therapy with immunotherapy, demonstrating high specificity and low side effects. The nanoparticles can target and destroy cancer cells while also stimulating the immune system to fight against tumors.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers found all hallmarks of T cell exhaustion within six to 12 hours of tumor exposure, including dramatic changes in gene expression and chromatin accessibility. The study challenges existing ideas about how T cells become exhausted and has implications for cancer immunotherapies.
Researchers discovered a protein called TRPM4 that strongly signals the immune system to target and clean up dying cancer cells. This finding may enhance immunotherapies against solid tumors by promoting necrosis, a type of cell death that activates immune cells.
Researchers discovered GDF-15 blocks LFA-1 dependent T cell recruitment into the tumor microenvironment, impairing immune responses to anti-PD-1 treatment. Visugromab improved T cell infiltration and increased tumor clearance with a synergistic effect
The updated guidelines urge the clinical use of validated geriatric assessments (GA) to guide treatments in patients aged 65 and older. This approach often results in de-escalation or reduction of therapies, reducing side effects and improving quality of life without compromising survival odds.
A new analysis found that combining weight-based dosing and shared single-use vials in VA hospitals could reduce cancer spending by 14%. This concept could be applied nationwide to improve cost-effectiveness of cancer care.
A phase I trial found that combining fecal transplants with immunotherapy is safe and shows promise in improving clinical responses in 65% of patients. The study used healthy donor microbiome to enhance immune system attack on cancer, offering a new paradigm shift in melanoma treatment.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
A new study from Sanford Burnham Prebys identified a protein called NR2F6 that helps melanoma cells evade the immune system, but also promotes anti-tumor immunity when targeted. The researchers hope to develop new drugs that can block this protein's activity, potentially doubling the effectiveness of immunotherapy for melanoma patients.
Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Researchers found that patients producing high levels of Cystatin C, a protein linked to immune system suppression, had worse survival rates and were less likely to benefit from immunotherapy. This suggests that Cystatin C may play a role in the failure of cancer immunotherapy.
A new EIC project, CAR T-REX, will develop novel, scalable CAR T cell therapies for the treatment of solid tumors. The consortium aims to overcome current limitations, including high manufacturing costs and limited efficacy, through a novel paradigm for generating improved CAR T cells.
Researchers found that PD-1 helps prevent T cells from attacking healthy skin and may help reduce side effects of immunotherapies. The study used mouse models and skin biopsies to support the hypothesis that PD-1 functions as a gatekeeper for tissue homeostasis
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
A new study at Yale University reveals that PD-1 plays a critical role in preventing T cells from attacking healthy tissues. The findings could lead to the development of improved immunotherapies with reduced side effects.
Researchers identified three immune cell types within tumor niches that determine which patients respond positively to checkpoint blockade immunotherapy. The study may inform new approaches to cancer treatment.
Researchers have developed a sonodynamic cancer immunotherapy based on semiconducting polymer nanoparticles that can be activated by ultrasound, effectively treating orthotopic pancreatic cancer in mouse models. The treatment induces immunogenic cell death and kills cancer cells without causing excessive immune responses.
Researchers developed CrossDome, a tool that uses genetic and biochemical information to predict T-cell immunotherapy's impact on healthy cells. The tool identified high-risk candidates in cases where treatments mistakenly attacked heart cells.
CHOP researchers have developed stable, universal MHC-I molecules that can be produced rapidly at scale, allowing for the development of effective and universal immunotherapies. These engineered MHC-I molecules promote peptide exchange across multiple HLA allotypes, covering various forms.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
Researchers have found that dual immunotherapy, combining PD-1 and CTLA-4 inhibitors, is effective in treating recurrent or metastatic nasopharyngeal carcinoma (NPC). The treatment showed a response rate of 38% and improved overall survival in patients with low pre-treatment plasma EBV DNA levels.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
Researchers discovered that targeting specific blood vessel enzymes can enhance immunotherapy effectiveness and prevent breast cancer metastasis. By disabling the enzyme DNMT1 in blood vessels, doctors may bolster anti-tumor immune cells entry and increase patients' response to treatment.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.
Researchers at Karolinska Institutet have identified how memory killer cells are formed and found a correlation between their presence in cancer tissue and improved survival rates in people with melanoma. The study suggests that harnessing the potential of these cells could lead to more effective immunotherapy.
Researchers developed a bio-sensing technology that measures PD1 ligand functionality to predict patient response to anti-PD1 therapy. This technology enables accurate prediction of patient response and tailoring treatments accordingly, improving cancer patients' lives.
A pan-cancer single-cell T cell atlas provides a detailed picture of the heterogeneity of T cells within the tumor microenvironment, revealing a previously undescribed stress response state that appears to be less effective at fighting cancer. This new discovery highlights the need for further understanding of how these states contribu...
Penn Medicine researchers will present results from clinical trials for recurrent glioblastoma and metastatic breast cancer. Experts will also present studies on serious illness conversations, Medicaid expansion impact, and infertility among female oncologists.
Researchers developed a drug treatment that inhibits YTHDF2, improving results of radiation therapy and preventing progression of distant metastasis. The treatment also prevents the "bad-scopal" effect, where radiation causes distant tumors to metastasize.
A new CAR T cell design approach using machine learning and artificial intelligence is being developed to improve cancer treatment. The project aims to create a hybrid knowledge- and data-driven approach to guide the design of immunotherapeutic cells.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.
Researchers developed a computational platform called IRIS to discover tumor antigens from alternative RNA splicing, expanding cancer immunotherapy targets. Hundreds of predicted TCR targets were found to be presented by human leukocyte antigen molecules.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer, with patients experiencing significantly improved progression-free survival. The median PFS was 11.3 months for those on nivolumab and ipilimumab alone, compared to not yet reached in the three-drug group.
University of Pittsburgh researchers created a universal receptor system allowing T cells to recognize any cell surface target. This enables highly customizable CAR T cell and other immunotherapies for treating cancer and diseases, with potential applications in solid tumors.
Researchers have developed a new immunotherapy targeting tumour macrophages, which are immunosuppressive cells that weaken the immune system. The treatment, RImAb, reduces tumour growth and modifies the tumour microenvironment, offering potential for a new line of treatment for lung cancer patients.
A recent clinical trial showed that cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer, improving their quality of life. The treatment also reduced symptoms such as pain and cough, and delayed clinically meaningful deterioration.
Researchers discovered that gamma delta T cells can effectively combat triple-negative breast cancer by targeting stress-induced molecules and phosphoantigens. Counteracting metabolic changes with zolendronate makes immunotherapy more efficient.
Researchers developed a biomarker signature test to predict which bladder cancer tumors will respond to immunotherapy, potentially improving survival rates. The study identified three types of responsive tumors and two non-responsive ones, providing insights into potential new treatments.
Blinatumomab immunotherapy significantly improves the survival rate of babies with aggressive acute lymphoblastic leukemia (ALL), from 66% to 93%, while reducing side effects. The treatment is now standard for babies worldwide.
Researchers propose a new theory on how cancer cells actively adapt to evade the immune system, losing and gaining tumor-associated antigens. This adaptation makes it difficult for immunotherapies to target cancer cells effectively, but may also create new vulnerabilities that can be therapeutically targeted.
Research suggests that patients with advanced melanoma who receive immunotherapy medications may benefit from maintaining normal vitamin D levels. The study found a favorable response rate in 56% of patients with normal baseline vitamin D levels, compared to 36% with low levels.
TRIO Pharmaceuticals is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers with high unmet medical needs. The company's innovative approach selectively eliminates immunosuppressive cells, enhancing antitumor activity.
Researchers developed bottlebrush-like nanoparticles that deliver immunostimulatory drugs to tumors, provoking an immune response and slowing tumor growth. The approach avoids systemic inflammation, making it a potential solution for boosting immune system responses in cancer patients.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
A recent study found that immunotherapy alone resulted in a 89% favorable treatment response rate for patients with desmoplastic melanoma. This suggests that combination therapies may not be necessary for these patients, reducing the risk of toxicity.
A recent clinical trial found that nearly 90% of patients with unresectable desmoplastic melanoma responded to treatment with pembrolizumab. The immunotherapy drug showed impressive results in both treatable and inoperable cases, suggesting a promising treatment option for this rare form of skin cancer.
Researchers at Mass General Cancer Center presented recent breakthroughs in cancer treatment, including a new mutant-selective drug that targets PI3Kα inhibitors, and innovations in whole-genome sequencing and imaging-based evaluation of cancer dependencies. These findings aim to improve the effectiveness of immunotherapy and personali...
Recent studies have highlighted the importance of tumor microenvironment in developing and controlling triple negative breast cancer progression. Researchers suggest that technological advancements like genomics and epigenomics hold promise for overcoming TNBC's current limitations.
The study reveals that intratumoral natural killer cells' loss of membrane protrusions impairs their ability to recognize and kill tumor cells. Researchers developed a single-immunocyte mass spectrometry technology to detect the decrease in sphingomyelin, which can restore protrusion formation and improve NK cells' killing capacity.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
Researchers developed 'BioArm,' a portable 3D bioprinter for cancer research, which can print complex tumoroids in under 90 seconds. The device enables testing of immunotherapy treatments and mimics the tumor microenvironment.